STAT Plus: Akcea, a biotech that relies on gene-blocking tech, loses its three top executives in one fell swoop
ADOBE
They're out less than a year after the company launched its first FDA-approved drug, Tegsedi, which treats a rare disease known as hATTR.
No hay comentarios:
Publicar un comentario